Guyana vs Kyrgyzstan: HIV/AIDS deaths averted by antiretroviral therapy
Guyana
512.85 deaths
in 2024
Kyrgyzstan
473.11 deaths
in 2024
Guyana rank
93rd
Kyrgyzstan rank
95th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Guyana
- Kyrgyzstan
How they compare
Guyana currently reports 512.85 deaths against 473.11 deaths in Kyrgyzstan, a difference of 39.74 deaths.
That makes Guyana's figure about 1.1 times Kyrgyzstan's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Kyrgyzstan ahead.
Guyana ranks 93rd and Kyrgyzstan ranks 95th of 157 countries.
Guyana has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Guyana | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 139.91 deaths | 6.55 deaths | 133.37 deaths | Guyana |
| 2010s | 424.71 deaths | 186.13 deaths | 238.58 deaths | Guyana |
| 2020s | 494.78 deaths | 412.22 deaths | 82.55 deaths | Guyana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Guyana or Kyrgyzstan?
- Guyana, at 512.85 deaths against 473.11 deaths in Kyrgyzstan as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Guyana and Kyrgyzstan?
- 39.74 deaths, with Guyana ahead.
- How many years of comparable data are there for Guyana and Kyrgyzstan?
- 35 years are reported by both, from 1990 to 2024.
- How do Guyana and Kyrgyzstan rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Guyana ranks 93rd and Kyrgyzstan ranks 95th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.